Sex disparities have been documented in lung cancer incidence [41] and sex may also influence treatment outcomes (such as in the case of epidermal growth factor receptor inhibitors and anti-programmed cell-death protein 1 (PD1) inhibitors) [42] or treatment complications [3]. Here, PDCD1 is linked to lung carcinoma.